Ma C. Targeting IL23p19 Using Risankizumab for the Management of Moderate-to-Severely Active Crohn’s Disease: The Next Frontier?. Can IBD Today [Internet]. 2023 May 11 [cited 2024 Nov. 23];1(S05):2–7. Available from: https://canadianibdtoday.com/article/view/1-s05-ma